What is Medixall's earnings per share (EPS)?

Medixall (MDXL) reported diluted earnings per share of $-0.04 for fiscal year 2023. This represents a 33.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Medixall Financials

MDXL

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2024 Currency USD FYE December

This page shows Medixall (MDXL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MDXL FY2023 2026-04-22

External financing rather than operations is carrying the business, with cash burn repeatedly matched by new funding.

Across FY2021-FY2023, financing cash inflows moved in near lockstep with operating cash outflows, narrowing from roughly $4M each to about $1.2M. That repeat pattern says the company has been replacing operating cash consumption with fresh capital instead of turning revenue into internal funding.

The improvement in FY2023 looks more like cost compression than operating scale: selling/admin expense fell to $1.0M from $3.2M, which helps explain the smaller burn. But a gross margin of 23.6% on just $309K of revenue still left too little contribution to absorb overhead. Interest expense of $647K was also larger than gross profit, so financing costs are weighing more heavily than the underlying service margin.

Liquidity is the sharper balance-sheet issue than growth: year-end cash was only $11K against current liabilities of $6.7M. Because nearly all liabilities were current and total assets were just $201K, the company appears dependent on continuous refinancing rather than on assets already on hand.

Financial Health Signals

Financial Profile 20/100

Based on FY2023 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Medixall's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

Medixall's revenue surged 422.1% year-over-year to $309K, reflecting rapid business expansion. This strong growth earns a score of 85/100.

Leverage

Medixall has a moderate D/E ratio of -1.03. This balance of debt and equity financing earns a leverage score of 35/100.

Liquidity

Medixall's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak

1/9

Medixall passes 1 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$309K

YoY+422.1%

5Y CAGR+178.2%

Medixall generated $309K in revenue in fiscal year 2023. This represents an increase of 422.1% from the prior year.

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.04

YoY+33.3%

Medixall earned $-0.04 per diluted share (EPS) in fiscal year 2023. This represents an increase of 33.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$11K

YoY+213.8%

5Y CAGR-44.4%

Medixall held $11K in cash against $0 in long-term debt as of fiscal year 2023.

Dividends Per Share

N/A

Shares Outstanding

130M

YoY+6.8%

5Y CAGR+13.4%

Medixall had 130M shares outstanding in fiscal year 2023. This represents an increase of 6.8% from the prior year.

Margins & Returns

Gross Margin

23.6%

YoY-76.4pp

Medixall's gross margin was 23.6% in fiscal year 2023, indicating the percentage of revenue retained after direct costs. This is down 76.4 percentage points from the prior year.

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

MDXL Income Statement

Metric	FY23	FY22	FY21	FY20	FY19	FY18
Revenue	$309K+422.1%	$59K-67.2%	$181K	$0-100.0%	$3K+44.5%	$2K
Cost of Revenue	$237K	$0	N/A	N/A	N/A	N/A
Gross Profit	$73K+23.0%	$59K	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$1.0M-68.6%	$3.2M+4.3%	$3.1M+21.2%	$2.5M+84.2%	$1.4M-19.7%	$1.7M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$647K+138.7%	$271K	$0	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	N/A	N/A
Net Income	N/A	N/A	N/A	-$5.9M-73.4%	-$3.4M-14.7%	-$3.0M
EPS (Diluted)	$-0.04+33.3%	$-0.060.0%	$-0.06	N/A	N/A	N/A

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Revenue	$39K-26.5%	$53K-55.3%	$118K+25.0%	$94K+44.2%	$66K-8.4%	$72K-8.1%	$78K+284.7%	$20K
Cost of Revenue	$17K+13.5%	$15K-71.1%	$50K+4.1%	$48K-23.3%	$63K+77.4%	$36K-60.2%	$89K	$0
Gross Profit	$22K-41.7%	$38K-43.5%	$68K+47.0%	$46K+1800.4%	$2K-93.3%	$36K+411.6%	-$12K-157.0%	$20K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$148K-10.5%	$166K-2.3%	$170K-52.3%	$356K+119.1%	$162K-23.4%	$212K-23.1%	$275K-54.9%	$611K
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$46K-56.6%	$106K-41.4%	$180K-62.0%	$475K+1184.8%	$37K+12.3%	$33K-67.7%	$102K-62.4%	$271K
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	$264K+154.3%	-$486K+0.2%	-$487K	N/A	-$908K+7.3%	-$979K+19.8%	-$1.2M	N/A
EPS (Diluted)	$0.00	$0.00	$0.00	N/A	$-0.010.0%	$-0.010.0%	$-0.01	N/A

MDXL Balance Sheet

Metric	FY23	FY22	FY21	FY20	FY19	FY18
Total Assets	$201K-76.7%	$862K-23.8%	$1.1M-31.1%	$1.6M+75.2%	$938K+28.7%	$729K
Current Assets	$14K+23.5%	$11K-96.6%	$343K-69.8%	$1.1M+154.1%	$446K+23.2%	$362K
Cash & Equivalents	$11K+213.8%	$3K-94.6%	$63K-90.2%	$646K+44.7%	$446K+121.4%	$202K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.7M+48.4%	$4.5M+207.9%	$1.5M+16.7%	$1.3M+133.5%	$540K+190.8%	$186K
Current Liabilities	$6.7M+54.3%	$4.3M+254.3%	$1.2M+9.3%	$1.1M+127.0%	$494K+165.9%	$186K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$6.5M-77.8%	-$3.7M-978.8%	-$340K-189.1%	$382K-4.0%	$398K-26.7%	$543K
Retained Earnings	-$37.2M-14.0%	-$32.6M-26.5%	-$25.8M-31.7%	-$19.6M-43.5%	-$13.6M-33.4%	-$10.2M

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Total Assets	$220K-4.1%	$229K-15.6%	$272K+35.1%	$201K-55.9%	$456K-7.3%	$492K-20.5%	$618K-28.3%	$862K
Current Assets	$47K+9.1%	$43K-40.3%	$72K+407.5%	$14K+8.0%	$13K-40.4%	$22K+282.1%	$6K-49.8%	$11K
Cash & Equivalents	$32K-2.2%	$33K-39.4%	$54K+401.9%	$11K+10.9%	$10K-48.0%	$19K+711.4%	$2K-33.0%	$3K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$12K+66.6%	$7K-53.2%	$15K	$0	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.8M-50.3%	$7.7M+6.1%	$7.3M+8.3%	$6.7M+17.9%	$5.7M+7.0%	$5.3M+6.8%	$5.0M+10.1%	$4.5M
Current Liabilities	$3.8M-50.6%	$7.7M+6.4%	$7.2M+7.8%	$6.7M+17.4%	$5.7M+7.0%	$5.3M+6.8%	$5.0M+14.9%	$4.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$3.6M+51.7%	-$7.5M-6.9%	-$7.0M-7.5%	-$6.5M-24.3%	-$5.2M-8.5%	-$4.8M-10.6%	-$4.4M-19.2%	-$3.7M
Retained Earnings	-$39.0M-2.2%	-$38.1M-1.3%	-$37.7M-1.3%	-$37.2M-4.1%	-$35.7M-2.6%	-$34.8M-2.9%	-$33.8M-3.7%	-$32.6M

MDXL Cash Flow Statement

Metric	FY23	FY22	FY21	FY20	FY19	FY18
Operating Cash Flow	-$1.2M+65.5%	-$3.6M+24.0%	-$4.7M-13.5%	-$4.1M-76.2%	-$2.3M-5.2%	-$2.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0+100.0%	-$1K+89.3%	-$13K+86.0%	-$92K-481.6%	-$16K+94.4%	-$282K
Financing Cash Flow	$1.2M-64.7%	$3.5M-14.9%	$4.1M-6.8%	$4.4M+69.8%	$2.6M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Operating Cash Flow	-$398K-35.2%	-$294K+4.7%	-$309K-53.3%	-$201K+23.7%	-$264K+16.4%	-$316K+29.6%	-$448K+25.1%	-$598K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1K
Financing Cash Flow	$397K+45.4%	$273K-22.4%	$352K+73.8%	$203K-20.6%	$255K-23.2%	$332K-25.7%	$447K-15.2%	$527K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MDXL Financial Ratios

Metric	FY23	FY22	FY21	FY20	FY19	FY18
Gross Margin	23.6%-76.4pp	100.0%	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	-127409.7%+33162.4pp	-160572.1%
Return on Equity	N/A	N/A	N/A	-1553.3%-693.2pp	-860.1%-310.6pp	-549.5%
Return on Assets	N/A	N/A	N/A	-360.9%+3.8pp	-364.7%+44.7pp	-409.4%
Current Ratio	0.000.0	0.00-0.3	0.28-0.7	1.01+0.1	0.90-1.0	1.95
Debt-to-Equity	-1.03+0.2	-1.23+3.1	-4.33-7.6	3.30+1.9	1.36+1.0	0.34
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Gross Margin	57.4%-15.0pp	72.4%+15.1pp	57.3%+8.6pp	48.8%+45.1pp	3.7%-46.5pp	50.2%+65.1pp	-14.8%-114.8pp	100.0%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	678.9%+1598.4pp	-919.5%-507.6pp	-411.9%	N/A	-1385.6%-16.3pp	-1369.3%+199.4pp	-1568.7%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	119.9%+331.8pp	-211.9%-32.8pp	-179.1%	N/A	-199.4%-0.1pp	-199.2%-1.6pp	-197.6%	N/A
Current Ratio	0.010.0	0.010.0	0.010.0	0.000.0	0.000.0	0.000.0	0.000.0	0.00
Debt-to-Equity	-1.06-0.0	-1.030.0	-1.040.0	-1.03+0.1	-1.09+0.0	-1.10+0.0	-1.14+0.1	-1.23
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$6.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Cardiocomm Solut EKGGF

$1.4M

EvokAI Creative OKAIF

$908K

Ppj Healthcare PPJE

$890K

Newtopia NEWUF

$87K

Mednow MDNWF

$517K

Frequently Asked Questions

What is Medixall's annual revenue?

Medixall (MDXL) reported $309K in total revenue for fiscal year 2023. This represents a 422.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Medixall's revenue growing?

Medixall (MDXL) revenue grew by 422.1% year-over-year, from $59K to $309K in fiscal year 2023.

What is Medixall's gross margin?

Medixall (MDXL) had a gross margin of 23.6% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.

What is Medixall's operating cash flow?

Medixall (MDXL) generated -$1.2M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.

What are Medixall's total assets?

Medixall (MDXL) had $201K in total assets as of fiscal year 2023, including both current and long-term assets.

How many shares does Medixall have outstanding?

Medixall (MDXL) had 130M shares outstanding as of fiscal year 2023.

What is Medixall's current ratio?

Medixall (MDXL) had a current ratio of 0.00 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.

What is Medixall's debt-to-equity ratio?

Medixall (MDXL) had a debt-to-equity ratio of -1.03 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Medixall's cash runway?

Based on fiscal year 2023 data, Medixall (MDXL) had $11K in cash against an annual operating cash burn of $1.2M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Medixall's debt-to-equity ratio negative or unusual?

Medixall (MDXL) has negative shareholder equity of -$6.5M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Medixall's Piotroski F-Score?

Medixall (MDXL) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

How financially healthy is Medixall?

Medixall (MDXL) scores 20 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.